Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out mali...
Estradiol transdermal system (twice-weekly) is indicated for: When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products. When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of oste...
Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestogen to reduce the risk of endometrial cancer. Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy. In some cases, however, hysterectomized women who have a history of endometriosis may need a progestogen [see Warnings and Precautions (5.2 , 5.14) ] ....
Estradiol Transdermal System, USP (Twice-Weekly) is available as 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day or 0.1 mg/day of estradiol. Each strength is supplied in a Patient Calendar Pack containing 8 individually packaged systems. The 0.025 mg per day is available as a 2.5 cm 2 system containing estradiol, USP hemihydrate equivalent to 0.41 mg of estradiol, for nominal* delivery of 0.025 mg of estrad...
www.nhlbi.nih.gov/whiEstrogen-Alone Therapy
Endometrial Cancer
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].
Cardiovascular Disorders and Probable Dementia
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.3)].
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.4)].
Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.3, 14.4)].
Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.
Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen Plus Progestin Therapy
Cardiovascular Disorders and Probable Dementia
The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.3)].
The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.4)].
Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.3, 14.4)].
Breast Cancer
The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2), and Clinical Studies (14.3)].
Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile.
Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estradiol transdermal system (twice-weekly) is indicated for:
When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products.
When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.
Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestogen to reduce the risk of endometrial cancer. Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy. In some cases, however, hysterectomized women who have a history of endometriosis may need a progestogen [see Warnings and Precautions (5.2, 5.14)].
Use estrogen-alone or in combination with a progestogen at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman. Reevaluate postmenopausal women periodically as clinically appropriate to determine whether treatment is still necessary.
Start therapy with estradiol transdermal system (twice-weekly) 0.0375 mg per day applied to the skin twice weekly. Make dosage adjustments based on the clinical response. Initiate estradiol transdermal system (twice-weekly) at once in a woman not currently taking oral estrogens or in a woman switching from another estradiol transdermal therapy. In women who are currently taking oral estrogens, initiate treatment with estradiol transdermal system (twice-weekly) 1 week after withdrawal of oral hormone therapy, or sooner if menopausal symptoms reappear in less than 1 week. Attempts to taper or discontinue estradiol transdermal system (twice-weekly) at 3 to 6-month intervals.
Give estradiol transdermal system (twice-weekly) continuously in a woman who does not have an intact uterus. In a woman with an intact uterus, give estradiol transdermal system (twice-weekly) on a cyclic schedule (for example, 3 weeks on estradiol transdermal system (twice-weekly) followed by 1 week off estradiol transdermal system (twice-weekly)).
Start therapy with estradiol transdermal system (twice-weekly) 0.0375 mg per day applied to the skin twice weekly. Dosage adjustment should be guided by the clinical response. Attempts to taper or discontinue estradiol transdermal system (twice-weekly) at 3 to 6-month intervals.
In women not currently taking oral estrogens or in women switching from another estradiol transdermal therapy, treatment with estradiol transdermal system (twice-weekly) may be initiated at once. In women who are currently taking oral estrogens, initiate treatment with estradiol transdermal system (twice-weekly) 1 week after withdrawal of oral hormone therapy, or sooner if menopausal symptoms reappear in less than 1 week.
Give estradiol transdermal system (twice-weekly) continuously in a woman who does not have an intact uterus. In a woman with an intact uterus, give estradiol transdermal system (twice-weekly) on a cyclic schedule (for example, 3 weeks on estradiol transdermal system (twice-weekly) followed by 1 week off estradiol transdermal system (twice-weekly)).
Start therapy with estradiol transdermal system (twice-weekly) 0.025 mg per day applied to the skin twice weekly.
In women not currently taking oral estrogens or in women switching from another estradiol transdermal therapy, treatment with estradiol transdermal system (twice-weekly) may be initiated at once. In women who are currently taking oral estrogens, initiate treatment with estradiol transdermal system (twice-weekly) 1 week after withdrawal of oral hormone therapy, or sooner if menopausal symptoms reappear in less than 1 week.
Estradiol transdermal system (twice-weekly) may be given continuously in a woman who does not have an intact uterus. In a woman with an intact uterus, estradiol transdermal system (twice-weekly) may be given on a cyclic schedule (for example, 3 weeks on estradiol transdermal system (twice-weekly) followed by 1 week off estradiol transdermal system (twice-weekly)).
Place the adhesive side of estradiol transdermal system (twice-weekly) on a clean, dry area of the trunk of the body (including the abdomen or buttocks). Do not apply estradiol transdermal system (twice-weekly) to the breasts.
Replace estradiol transdermal system (twice-weekly) twice weekly. Rotate the sites of application, with an interval of at least 1 week allowed between applications to a particular site. Select an area that is not oily, damaged, or irritated. Avoid the waistline, since tight clothing may rub the system off. Apply the system immediately after opening the pouch and removing the oversized protective liner. Press the system firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges.
In the event that a system falls off, reapply the same system or apply a new system to another location. In either case, continue the original treatment schedule. If a woman has forgotten to apply estradiol transdermal system (twice-weekly), have her apply a new system as soon as possible. Apply the new system on the original treatment schedule. The interruption of treatment in women taking estradiol transdermal system (twice-weekly) might increase the likelihood of breakthrough bleeding, spotting and recurrence of symptoms.
Estradiol Transdermal System, USP (Twice-Weekly) is available as 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, or 0.1 mg/day of estradiol.
[*see DESCRIPTION (11)]
Estradiol transdermal system (twice-weekly) is contraindicated in women with any of the following conditions:
Increased risks of stroke and DVT are reported with estrogen-alone therapy. Increased risks of PE, DVT, stroke, and MI are reported with estrogen plus progestin therapy. Immediately discontinue estrogen with or without progestogen therapy if any of these occur or are suspected.
Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus).
The WHI estrogen-alone substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 strokes per 10,000 women-years, respectively). The increase in risk was demonstrated in year 1 and persisted [see Clinical Studies (14.3)]. Immediately discontinue estrogen-alone therapy if a stroke occurs or is suspected.
Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).1
The WHI estrogen plus progestin substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 strokes per 10,000 women-years) [see Clinical Studies (14.3)]. The increase in risk was demonstrated after the first year and persisted.1 Immediately discontinue estrogen plus progestogen therapy if a stroke occurs or is suspected.
The WHI estrogen-alone substudy reported no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) in women receiving estrogen-alone compared to placebo2 [see Clinical Studies (14.3)].
Subgroup analyses of women 50 to 59 years of age, who were less than 10 years since menopause, suggest a reduction (not statistically significant) in CHD events in those women receiving daily CE (0.625 mg)–alone compared to placebo (8 versus 16 per 10,000 women-years).1
The WHI estrogen plus progestin substudy reported an increased risk (not statistically significant) in CHD events in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see Clinical Studies (14.3)].
In postmenopausal women with documented heart disease (n = 2,763, average 66.7 years of age), in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred twenty-one (2,321) women from the original HERS trial agreed to participate in an open-label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in the HERS, the HERS II, and overall.
In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE) was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years3 [see Clinical Studies (14.3)]. Immediately discontinue estrogen-alone therapy if a VTE occurs or is suspected.
The WHI estogen plus progestin substudy reported a statistically significant 2-fold greater rate of VTE in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted4 [see Clinical Studies (14.3)]. Immediately discontinue estrogen plus progestogen therapy if a VTE occurs or is suspected.
If feasible, discontinue estrogens at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.
An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with the use of estrogens for less than 1 year. The greatest risk appears to be associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more, and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.
Clinical surveillance of all women using estrogen-alone or estrogen plus progestogen therapy is important. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding with unknown etiology. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.
The WHI substudy of daily CE (0.625 mg)-alone provided information about breast cancer in estrogen-alone users. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80)5 [see Clinical Studies (14.3)].
After a mean follow-up of 5.6 years, the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily CE plus MPA compared to placebo.
In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26% of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo.6 Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade, and hormone receptor status did not differ between the groups6 [see Clinical Studies (14.3)].
Consistent with the WHI clinical trial, observational studies have also reported an increased risk of breast cancer with estrogen plus progestin therapy, and a smaller increase in the risk for breast cancer with estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to > 10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy. Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. These studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.
The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.
The CE plus MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for CE plus MPA versus placebo was 1.58 (95% CI, 0.77-3.24), but it was not statistically significant. The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.7
A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.
In the WHI Memory Study (WHIMS) estrogen-alone ancillary study, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo.
After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95% CI, 0.83 to 2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years8 [see Use in Specific Populations (8.5), and Clinical Studies (14.4)].
In the WHIMS estrogen plus progestin ancillary study of WHI, a population of 4,532 postmenopausal women 65 to 79 years was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo.
After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95% CI, 1.21 to 3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years8 [see Use in Specific Populations (8.5), and Clinical Studies (14.4)].
When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95% CI, 1.19 to 2.60). Since both ancillary studies were conducted in women aged 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see Use in Specific Populations (8.5), and Clinical Studies (14.4)].
A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.
Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases. Discontinue estrogens, including estradiol transdermal system (twice-weekly), if hypercalcemia occurs, and take appropriate measures to reduce the serum calcium level.
Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue estradiol transdermal (twice-weekly) pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. Permanently discontinue estrogens, including estradiol transdermal system (twice-weekly), if examination reveals papilledema or retinal vascular lesions.
Studies of the addition of a progestogen for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer.
There are, however, possible risks that may be associated with the use of progestogens with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer.
In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen.
In women with preexisting hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Discontinue estradiol transdermal (twice-weekly) if pancreatitis occurs.
Estrogens may be poorly metabolized in women with hepatic impairment. Exercise caution in any woman with a history of cholestatic jaundice associated with past estrogen use or with pregnancy. In the case of recurrence of cholestatic jaundice, discontinue estradiol transdermal system (twice-weekly).
Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. Monitor thyroid function in these women during treatment with estradiol transdermal system (twice-weekly) to maintain their free thyroid hormone levels in an acceptable range.
Estrogens may cause some degree of fluid retention. Monitor any woman with a condition(s) that might predispose her to fluid retention, such as cardiac or renal impairment. Discontinue estrogen-alone therapy, including estradiol transdermal system (twice-weekly), with evidence of medically concerning fluid retention.
Estrogen-induced hypocalcemia may occur in women with hypoparathyroidism. Consider whether the benefits of estrogen therapy, including estradiol transdermal system (twice-weekly), outweigh the risks in such women.
A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. Consider the addition of progestogen therapy for women known to have residual endometriosis post-hysterectomy.
A few cases of anaphylactic/anaphylactoid reactions are reported in the postmarketing use of estradiol transdermal system (twice-weekly). Involvement of skin (hives, pruritus, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting) are noted.
Angioedema involving eye/eyelid, face, larynx, pharynx, tongue and extremity (hands, legs, ankles, and fingers) with or without urticaria requiring medical intervention are reported in the postmarketing use of estradiol transdermal system (twice-weekly). Angioedema involving the tongue, glottis, or larynx, may result in airway obstruction. Do not give estradiol transdermal system (twice-weekly) to any woman who develops angioedema during treatment with estradiol transdermal system (twice-weekly).
Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. Consider whether the benefits of estrogen therapy outweigh the risks in such women.
Estrogen therapy, including estradiol transdermal system (twice-weekly), may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraines, porphyria, systemic lupus erythematosus, and hepatic hemangiomas. Consider whether the benefits of estrogen therapy outweigh the risks in such women.
Serum follicle-stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy.
Laboratory parameters may be useful in guiding dosage for the treatment of hypoestrogenism due to hypogonadism, castration and primary ovarian failure.
The following serious adverse reactions are discussed elsewhere in labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
There were no clinical trials conducted with the revised formulation of estradiol transdermal system (twice-weekly). The revised formulation of estradiol transdermal system (twice-weekly) is bioequivalent to the original formulation of estradiol transdermal system (twice-weekly). The following adverse reactions have been reported with the original formulation of estradiol transdermal system (twice-weekly) therapy:
Estradiol Transdermal System (Twice-Weekly) | Placebo | |||||
0.025 mg/day* | 0.0375 mg/day | 0.05 mg/day | 0.075 mg/day | 0.1 mg/day | ||
(N = 47) | (N = 130) | (N = 103) | (N = 46) | (N = 132) | (N = 157) | |
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Gastrointestinal disorders | ||||||
Constipation | 2 (4.3) | 5 (3.8) | 4 (3.9) | 3 (6.5) | 2 (1.5) | 4 (2.5) |
Dyspepsia | 4 (8.5) | 12 (9.2) | 3 (2.9) | 2 (4.3) | 0 | 10 (6.4) |
Nausea | 2 (4.3) | 8 (6.2) | 4 (3.9) | 0 | 7 (5.3) | 5 (3.2) |
General disorders and administration site conditions† | ||||||
Influenza-like illness | 3 (6.4) | 6 (4.6) | 8 (7.8) | 0 | 3 (2.3) | 10 (6.4) |
Pain NOS‡ | 0 | 8 (6.2) | 0 | 2 (4.3) | 7 (5.3) | 7 (4.5) |
Infections and infestations | ||||||
Influenza | 4 (8.5) | 4 (3.1) | 6 (5.8) | 0 | 10 (7.6) | 14 (8.9) |
Nasopharyngitis | 3 (6.4) | 16 (12.3) | 10 (9.7) | 9 (19.6) | 11 (8.3) | 24 (15.3) |
Sinusitis NOS | 4 (8.5) | 17 (13.1) | 13 (12.6) | 3 (6.5) | 7 (5.3) | 16 (10.2) |
Upper respiratory tract infection NOS | 3 (6.4) | 8 (6.2) | 11 (10.7) | 4 (8.7) | 6 (4.5) | 9 (5.7) |
Investigations | ||||||
Weight increased | 4 (8.5) | 5 (3.8) | 2 (1.9) | 2 (4.3) | 0 | 3 (1.9) |
Musculoskeletal and connective tissue disorders | ||||||
Arthralgia | 0 | 11 (8.5) | 4 (3.9) | 2 (4.3) | 5 (3.8) | 9 (5.7) |
Back pain | 4 (8.5) | 10 (7.7) | 9 (8.7) | 4 (8.7) | 14 (10.6) | 10 (6.4) |
Neck pain | 3 (6.4) | 4 (3.1) | 4 (3.9) | 0 | 6 (4.5) | 2 (1.3) |
Pain in limb | 0 | 10 (7.7) | 7 (6.8) | 2 (4.3) | 6 (4.5) | 9 (5.7) |
Nervous system disorders | ||||||
Headache NOS | 7 (14.9) | 35 (26.9) | 32 (31.1) | 23 (50.0) | 34 (25.8) | 37 (23.6) |
Sinus headache | 0 | 12 (9.2) | 5 (4.9) | 5 (10.9) | 2 (1.5) | 8 (5.1) |
Psychiatric disorders | ||||||
Anxiety NEC§ | 3 (6.4) | 5 (3.8) | 0 | 0 | 2 (1.5) | 4 (2.5) |
Depression | 5 (10.6) | 4 (3.1) | 7 (6.8) | 0 | 4 (3.0) | 6 (3.8) |
Insomnia | 3 (6.4) | 6 (4.6) | 4 (3.9) | 2 (4.3) | 2 (1.5) | 9 (5.7) |
Reproductive system and breast disorders | ||||||
Breast tenderness | 8 (17.0) | 10 (7.7) | 8 (7.8) | 3 (6.5) | 17 (12.9) | 0 |
Dysmenorrhea | 0 | 0 | 0 | 3 (6.5) | 0 | 0 |
Intermenstrual bleeding | 3 (6.4) | 9 (6.9) | 6 (5.8) | 0 | 14 (10.6) | 7 (4.5) |
Respiratory, thoracic and mediastinal disorders | ||||||
Sinus congestion | 0 | 4 (3.1) | 3 (2.9) | 3 (6.5) | 6 (4.5) | 7 (4.5) |
Vascular disorders | ||||||
Hot flushes NOS | 3 (6.4) | 0 | 3 (2.9) | 0 | 0 | 6 (3.8) |
Hypertension NOS | 2 (4.3) | 0 | 3 (2.9) | 0 | 0 | 2 (1.3) |
* Represents milligrams of estradiol delivered daily by each system.
† Application site erythema and application site irritation were observed in a small number of patients (3.2% or less of patients across treatment groups).
‡ NOS represents not otherwise specified.
§ NEC represents not elsewhere classified.
The following additional adverse reactions have been identified during post-approval use of estradiol transdermal system (twice-weekly). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Genitourinary System
Vaginal hemorrhage and abnormal withdrawal bleeding or flow, breakthrough bleeding, spotting, uterine leiomyomata, vaginitis, vaginal discharge, ovarian cancer, endometrial hyperplasia, dysmenorrhea.
Breast
Enlargement, pain, nipple discharge, fibrocystic breast changes, breast cancer.
Cardiovascular
Deep venous thrombosis, pulmonary embolism, thrombophlebitis.
Gastrointestinal
Nausea, vomiting, abdominal cramps, bloating, cholelithiasis, liver function tests abnormal, diarrhea.
Skin
Application site reactions include localized bleeding, bruising, burning, discomfort, dryness, eczema, edema, erythema, erythema multiforme, erythema nodosum, inflammation, irritation, pain, papules and vesicles. Other skin reactions include paresthesia, skin discoloration, skin pigmentation, urticaria, swelling, loss of scalp hair, hirsutism, pruritus, and rash.
Eyes
Intolerance to contact lenses.
Central Nervous System
Migraine, dizziness, chorea, nervousness, affect liability, irritability.
Miscellaneous
Decrease in weight, reduced carbohydrate tolerance, edema, arthralgias, leg cramps, changes in libido, purpura, hypersensitivity, anaphylactic reaction, anaphylactoid reaction, angioedema.
In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John’s wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice may increase plasma concentrations of estrogens and may result in adverse reactions.
Estradiol transdermal system (twice-weekly) is not indicated for use in pregnancy. There are no data with the use of estradiol transdermal system (twice-weekly) in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Estrogens are present in human milk and can reduce milk production in breast-feeding women. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for estradiol transdermal system (twice-weekly) and any potential adverse effects on the breastfed child from estradiol transdermal system (twice-weekly) or from the underlying maternal condition.
Estradiol transdermal system (twice-weekly) is not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population.
If estrogen is administered to patients whose bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended during estrogen administration.
There have not been sufficient numbers of geriatric women involved in clinical studies utilizing estradiol transdermal system (twice-weekly) to determine whether those over 65 years of age differ from younger subjects in their response to estradiol transdermal system (twice-weekly).
In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Warnings and Precautions (5.1), and Clinical Studies (14.3)].
In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Warnings and Precautions (5.1), and Clinical Studies (14.3)].
In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see Warnings and Precautions (5.3), and Clinical Studies (14.4)].
Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see Warnings and Precautions (5.3), and Clinical Studies (14.4)].
Overdosage of estrogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of estradiol transdermal system (twice-weekly) therapy with institution of appropriate symptomatic care.
Estradiol Transdermal System, USP (twice-weekly) contains estradiol hemihydrate in a multipolymeric adhesive. The system is designed to release estradiol continuously upon application to intact skin.
Five dosage strengths of estradiol transdermal system (twice-weekly) are available to provide nominal in vivo delivery rates of 0.025, 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per day via the skin. Each corresponding system has an active surface area of 2.5, 3.75, 5.0, 7.5, or 10.0 cm2 and contains estradiol, USP hemihydrate equivalent to 0.41, 0.62, 0.82, 1.23, or 1.64 mg of estradiol, respectively. The composition of the systems per unit area is identical.
Estradiol, USP hemihydrate is a white, crystalline powder, chemically described as Estra-1,3,5(10)-triene-3,17β-diol-hemihydrate.
The structural formula is:
The molecular formula of estradiol hemihydrate is C18H24O2 • ½ H2O. The molecular weight is 281.39.
Meets USP Drug Release Test 4.
Estradiol transdermal system (twice-weekly) is comprised of 3 layers. Proceeding from the visible surface toward the surface attached to the skin, these layers are (1) a translucent polyolefin film printed with brown ink, (2) an adhesive formulation containing estradiol, silicone adhesive, acrylic adhesive, dipropylene glycol, povidone and oleyl alcohol, and (3) an oversized slit polyester release liner which is attached to the adhesive surface and must be removed before the system can be used.
The active component of the system is estradiol. The remaining components of the system are pharmacologically inactive.
Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.
The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.
Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, 2 estrogen receptors have been identified. These vary in proportion from tissue to tissue.
Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.
Generally, a serum estrogen concentration does not predict an individual woman’s therapeutic response to estradiol transdermal system (twice-weekly) nor her risk for adverse outcomes. Likewise, exposure comparisons across different estrogen products to infer efficacy or safety for the individual woman may not be valid.
In a multiple-dose study consisting of 3 consecutive system applications of the original formulation of estradiol transdermal system (twice-weekly) which was conducted in 17 healthy, postmenopausal women, blood levels of estradiol and estrone were compared following application of these units to sites on the abdomen and buttocks in a crossover fashion. Systems that deliver nominal estradiol doses of approximately 0.0375 mg per day and 0.1 mg per day were applied to abdominal application sites while the 0.1 mg per day doses were also applied to sites on the buttocks. These systems increased estradiol levels above baseline within 4 hours and maintained respective mean levels of 25 and 79 pg/mL above baseline following application to the abdomen; slightly higher mean levels of 88 pg/mL above baseline were observed following application to the buttocks. At the same time, increases in estrone plasma concentrations averaged about 12 and 50 pg/mL, respectively, following application to the abdomen and 61 pg/mL for the buttocks. While plasma concentrations of estradiol and estrone remained slightly above baseline at 12 hours following removal of the systems in this study, results from another study show these levels to return to baseline values within 24 hours following removal of the systems.
Figure 1 illustrates the mean plasma concentrations of estradiol at steady-state during application of these patches at 4 different dosages.
The corresponding pharmacokinetic parameters are summarized in Table 2.
Dosage | Cmax † | Cavg ‡ | Cmin (84 hr)§ |
(mg/day) | (pg/mL) | (pg/mL) | (pg/mL) |
0.0375 | 46 ± 16 | 34 ± 10 | 30 ± 10 |
0.05 | 83 ± 41 | 57 ± 23¶ | 41 ± 11 |
0.075 | 99 ± 35 | 72 ± 24 | 60 ± 24 |
0.1 | 133 ± 51 | 89 ± 38 | 90 ± 44 |
0.1# | 145 ± 71 | 104 ± 52 | 85 ± 47 |
* Mean baseline estradiol concentration = 11.7 pg/mL.
† Peak plasma concentration.
‡ Average plasma concentration.
§ Minimum plasma concentration at 84 hr.
¶ Measured over 80 hr.
# Applied to the buttocks.
Estradiol transdermal system (twice-weekly), the revised formulation with smaller system sizes, was shown to be bioequivalent to the original formulation of estradiol transdermal system (twice-weekly) used in the clinical trials.
The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to sex hormone-binding globulin (SHBG) and albumin.
Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver by Cytochrome 450 isoforms CYP1A2 and CYP3A4. Estradiol undergoes further metabolism to sulfate and glucuronide conjugates. Estradiol and its metabolites are glucuronidated by UGT1A1 and UGT2B7. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.
Estradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates. The half-life values calculated after dosing with the estradiol transdermal system (twice-weekly) ranged from 5.9 to 7.7 hours. After removal of the transdermal systems, serum concentrations of estradiol and estrone returned to baseline levels within 24 hours.
Based upon a dermal study for adhesion characteristics in 228 subjects, approximately 96% of estradiol transdermal system 0.025 mg/day (twice-weekly) patches adhered essentially complete (defined as greater than or equal to 90% adhered) to the skin over the 3.5-day wear period. Approximately 1% of the systems detached during the 3.5-day wear period.
Long-term, continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.
In a pharmacokinetic study, the revised formulation of estradiol transdermal system (twice-weekly) was shown to be bioequivalent to the original formulation of estradiol transdermal system (twice-weekly). In 2 controlled clinical trials with the original formulation of estradiol transdermal system (twice-weekly), of 356 women, the 0.075 and 0.1 mg doses were superior to placebo in relieving vasomotor symptoms at Week 4, and maintained efficacy through Weeks 8 and 12 of treatment. In this original study, the 0.0375 and 0.05 mg doses, however, did not differ from placebo until approximately Week 6, therefore, an additional 12-week, placebo-controlled study in 255 women was performed with estradiol transdermal system (twice-weekly) to establish the efficacy of the lowest dose of 0.0375 mg. The baseline mean daily number of hot flushes in these 255 women was 11.5. Results at Weeks 4, 8, and 12 of treatment are shown in Figure 2.
The 0.0375 mg dose was superior to placebo in reducing both the frequency and severity of vasomotor symptoms at Week 4 and maintained efficacy through Weeks 8 and 12 of treatment. All doses of estradiol transdermal system (twice-weekly) (0.0375 mg, 0.05 mg, 0.075 mg, and 0.1 mg) are effective for the control of vasomotor symptoms.
Efficacy and safety of estradiol transdermal system (twice-weekly) in the prevention of postmenopausal osteoporosis have been studied in a 2-year, double-blind, randomized, placebo-controlled, parallel-group study. A total of 261 hysterectomized (161) and non-hysterectomized (100), surgically or naturally menopausal women (within 5 years of menopause), with no evidence of osteoporosis (lumbar spine bone mineral density within 2 standard deviations of average peak bone mass, i.e., at least 0.827 g/cm2) were enrolled in this study; 194 women were randomized to 1 of the 4 doses of estradiol transdermal system (twice-weekly) (0.1, 0.05, 0.0375, or 0.025 mg/day) and 67 patients to placebo. Over 2 years, study systems were applied to the buttock or the abdomen twice a week. Non-hysterectomized women received oral medroxyprogesterone acetate (2.5 mg/day) throughout the study.
The study population comprised naturally (82%) or surgically (18%) menopausal, hysterectomized (61%) or non-hysterectomized (39%) women with a mean age of 52 years (range 27 to 62 years); the mean duration of menopause was 31.7 months (range 2 to 72 months). Two hundred thirty-two (89%) of randomized women (173 on active drug, 59 on placebo) contributed data to the analysis of percent change from baseline in bone mineral density (BMD) of the AP lumbar spine, the primary efficacy variable. Women were given supplemental dietary calcium (1000 mg elemental calcium/day) but no supplemental vitamin D. There was an increase in BMD of the AP lumbar spine in all estradiol transdermal system (twice-weekly) dose groups; in contrast to this, a decrease in AP lumbar spine BMD was observed in placebo patients. All estradiol transdermal system (twice-weekly) doses were significantly superior to placebo (p < 0.05) at all time points with the exception of estradiol transdermal system (twice-weekly) 0.05 mg/day at 6 months. The highest dose of estradiol transdermal system (twice-weekly) was superior to the 3 lower doses. There were no statistically significant differences in pairwise comparisons among the 3 lower doses (see Figure 3).
Analysis of percent change from baseline in femoral neck BMD, a secondary efficacy outcome variable, showed qualitatively similar results; all doses of estradiol transdermal system (twice-weekly) were significantly superior to placebo (p < 0.05) at 24 months. The highest estradiol transdermal system (twice-weekly) dose was superior to placebo at all time points. A mixture of significant and nonsignificant results were obtained for the lower dose groups at earlier time points. The highest estradiol transdermal system (twice-weekly) dose was superior to the 3 lower doses, and there were no significant differences among the 3 lower doses at this skeletal site (see Figure 4).
The mean serum osteocalcin (a marker of bone formation) and urinary excretion of cross-link N-telopeptides of Type 1 collagen (a marker of bone resorption) decreased numerically in most of the active treatment groups relative to baseline. However, the decreases in both markers were inconsistent across treatment groups and the differences between active treatment groups and placebo were not statistically significant.
The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with the MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI, and CHD death), with invasive breast cancer as the primary adverse outcome. A “global index” included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other causes. These substudies did not evaluate the effects of CE-alone or CE plus MPA on menopausal symptoms.
The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints. Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3% White, 15.1% Black, 6.1% Hispanic, 3.6% Other) after an average follow-up of 7.1 years, are presented in Table 3.
CE | Placebo | ||
Event | Relative Risk | Absolute Risk per 10,000 Women-Years | |
CHD events‡ | 0.95 (0.78‒1.16) | 54 | 57 |
Non-fatal MI | 0.91 (0.73‒1.14) | 40 | 43 |
CHD death | 1.01 (0.71‒1.43) | 16 | 16 |
All strokes | 1.33 (1.05‒1.68) | 45 | 33 |
Ischemic stroke | 1.55 (1.19‒2.01) | 38 | 25 |
Deep vein thrombosis § | 1.47 (1.06‒2.06) | 23 | 15 |
Pulmonary embolism | 1.37 (0.90‒2.07) | 14 | 10 |
Invasive breast cancer | 0.80 (0.62‒1.04) | 28 | 34 |
Colorectal cancer¶ | 1.08 (0.75‒1.55) | 17 | 16 |
Hip fracture | 0.65 (0.45‒0.94) | 12 | 19 |
Vertebral fractures | 0.64 (0.44‒0.93) | 11 | 18 |
Lower arm/wrist fractures | 0.58 (0.47‒0.72) | 35 | 59 |
Total fractures | 0.71 (0.64‒0.80) | 144 | 197 |
Death due to other causes # | 1.08 (0.88‒1.32) | 53 | 50 |
Overall mortality | 1.04 (0.88‒1.22) | 79 | 75 |
Global Index♠ | 1.02 (0.92‒1.13) | 206 | 201 |
* Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.
† Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.
‡ Results are based on centrally adjudicated data for an average follow-up of 7.1 years.
§ Not included in “global index”.
¶ Results are based on an average follow-up of 6.8 years.
# All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.
♠ A subset of the events was combined in a “global index”, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.
For those outcomes included in the WHI “global index” that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures.9 The absolute excess risk of events included in the “global index” was a nonsignificant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality.
No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years (see Table 3).
Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant differences in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for ischemic stroke, and this excess risk was present in all subgroups of women examined10 (see Table 3).
Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age showed in women 50 to 59 years of age a nonsignificant trend toward reduced risk for CHD [hazard ratio (HR) 0.63 (95% CI, 0.36 to 1.09)] and overall mortality [HR 0.71 (95% CI, 0.46 to 1.11)].
The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the “global index”. The absolute excess risk of events included in the “global index” was 19 per 10,000 women-years.
For those outcomes included in the WHI “global index” that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reduction per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures.
Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79, 83.9% White, 6.8% Black, 5.4% Hispanic, 3.9% Other) are presented in Table 4. These results reflect centrally adjudicated data after an average follow-up of 5.6 years.
CE/MPA n = 8,506 | Placebo n = 8,102 | ||
Event | Relative Risk CE/MPA vs. Placebo (95% nCI‡) | Absolute Risk per 10,000 Women-Years | |
CHD events | 1.23 (0.99‒1.53) | 41 | 34 |
Non-fatal MI | 1.28 (1.00‒1.63) | 31 | 25 |
CHD death | 1.10 (0.70‒1.75) | 8 | 8 |
All strokes | 1.31 (1.03‒1.68) | 33 | 25 |
Ischemic Stroke | 1.44 (1.09‒1.90) | 26 | 18 |
Deep vein thrombosis§ | 1.95 (1.43‒2.67) | 26 | 13 |
Pulmonary embolism | 2.13 (1.45‒3.11) | 18 | 8 |
Invasive breast cancer¶ | 1.24 (1.01‒1.54) | 41 | 33 |
Colorectal cancer | 0.61 (0.42‒0.87) | 10 | 16 |
Endometrial cancer | 0.81 (0.48‒1.36) | 6 | 7 |
Cervical cancer | 1.44 (0.47‒4.42) | 2 | 1 |
Hip fracture | 0.67 (0.47‒0.96) | 11 | 16 |
Vertebral fractures | 0.65 (0.46‒0.92) | 11 | 17 |
Lower arm/wrist fractures | 0.71 (0.59‒0.85) | 44 | 62 |
Total fractures | 0.76 (0.69‒0.83) | 152 | 199 |
Overall mortality# | 1.00 (0.83‒1.19) | 52 | 52 |
Global Index♠ | 1.13 (1.02‒1.25) | 184 | 165 |
* Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.
† Results are based on centrally adjudicated data.
‡ Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.
§ Not included in “global index”.
¶ Includes metastatic and non-metastatic breast cancer, with the exception of in situ breast cancer.
# All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.
♠ A subset of the events was combined in a “global index”, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.
Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality [HR 0.69 (95% CI, 0.44 to 1.07)].
The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age and older (45% were age 65 to 69 years of age; 36% were 70 to 74 years of age; 19% were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo.
After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95% CI, 0.83 to 2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable dementia as defined in this study included Alzheimer’s disease (AD), vascular dementia (VaD), and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions (5.3) and Use in Specific Populations (8.5)].
The WHIMS estrogen plus progestin ancillary study enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47% were age 65 to 69 years of age; 35% were 70 to 74 years of age; 18% were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo.
After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA was 2.05 (95% CI, 1.21 to 3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 per 10,000 women-years. Probable dementia as defined in this study included AD, VaD, and mixed type (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions (5.3) and Use in Specific Populations (8.5)].
When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95% CI, 1.19 to 2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions (5.3) and Use in Specific Populations (8.5)].
Estradiol Transdermal System, USP (Twice-Weekly) is available as 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day or 0.1 mg/day of estradiol. Each strength is supplied in a Patient Calendar Pack containing 8 individually packaged systems.
The 0.025 mg per day is available as a 2.5 cm2 system containing estradiol, USP hemihydrate equivalent to 0.41 mg of estradiol, for nominal* delivery of 0.025 mg of estradiol per day. Each rectangular patch with rounded corners consists of an opaque, white to cream adhesive layer, matte film backing randomly printed with “Estradiol 0.025 mg/day” in brown ink, and a clear release liner. The patch is contained in a square, flat, notched, pouch. The pouch is imprinted with the lot number and expiration date. They are available as follows:
NDC 0378-4644-26
carton containing 8 systems
The 0.0375 mg per day is available as a 3.75 cm2 system containing estradiol, USP hemihydrate equivalent to 0.62 mg of estradiol for nominal* delivery of 0.0375 mg of estradiol per day. Each rectangular patch with rounded corners consists of an opaque, white to cream adhesive layer, matte film backing randomly printed with “Estradiol 0.0375 mg/day” in brown ink, and a clear release liner. The patch is contained in a square, flat, notched, pouch. The pouch is imprinted with the lot number and expiration date. They are available as follows:
NDC 0378-4643-26
carton containing 8 systems
The 0.05 mg per day is available as a 5.0 cm2 system containing estradiol, USP hemihydrate equivalent to 0.82 mg of estradiol for nominal* delivery of 0.05 mg of estradiol per day. Each rectangular patch with rounded corners consists of an opaque, white to cream adhesive layer, matte film backing randomly printed with “Estradiol 0.05 mg/day” in brown ink, and a clear release liner. The patch is contained in a square, flat, notched, pouch. The pouch is imprinted with the lot number and expiration date. They are available as follows:
NDC 0378-4642-26
carton containing 8 systems
The 0.075 mg per day is available as a 7.5 cm2 system containing estradiol, USP hemihydrate equivalent to 1.23 mg of estradiol for nominal* delivery of 0.075 mg of estradiol per day. Each rectangular patch with rounded corners consists of an opaque, white to cream adhesive layer, matte film backing randomly printed with “Estradiol 0.075 mg/day” in brown ink, and a clear release liner. The patch is contained in a square, flat, notched, pouch. The pouch is imprinted with the lot number and expiration date. They are available as follows:
NDC 0378-4641-26
carton containing 8 systems
The 0.1 mg per day is available as a 10.0 cm2 system containing estradiol, USP hemihydrate equivalent to 1.64 mg of estradiol for nominal* delivery of 0.1 mg of estradiol per day. Each rectangular patch with rounded corners consists of an opaque, white to cream adhesive layer, matte film backing randomly printed with “Estradiol 0.1 mg/day” in brown ink, and a clear release liner. The patch is contained in a square, flat, notched, pouch. The pouch is imprinted with the lot number and expiration date. They are available as follows:
NDC 0378-4640-26
carton containing 8 systems
[*see DESCRIPTION (11)]
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Do not store unpouched. Apply immediately upon removal from the protective pouch.
Used transdermal systems still contain active hormone. To discard, fold the sticky side of the transdermal system together, place it in a sturdy child-proof container, and place this container in the trash. Used transdermal systems should not be flushed in the toilet.
Advise women to read the FDA-approved patient labeling (Patient Information and Instructions for Use)
Vaginal Bleeding
Inform postmenopausal women to report any vaginal bleeding to their healthcare providers as soon as possible [see Warnings and Precautions (5.2)].
Possible Serious Adverse Reactions with Estrogen-Alone Therapy
Inform postmenopausal women of possible serious adverse reactions of estrogen-alone therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia [see Warnings and Precautions (5.1, 5.2, 5.3)].
Possible Common Adverse Reactions with Estrogen-Alone Therapy
Inform postmenopausal women of possible less serious but common adverse reactions of estrogen-alone therapy such as headache, breast pain and tenderness, nausea and vomiting.
Estradiol Transdermal System, USP (Twice-Weekly) | |
Read this Patient Information before you start using estradiol transdermal system (twice-weekly) and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. | |
What is the most important information I should know about estradiol transdermal system (twice-weekly) (an estrogen hormone)?
| |
What is estradiol transdermal system (twice-weekly)? Estradiol transdermal system (twice-weekly) is a prescription medicine patch (transdermal system) that contains the estrogen hormone estradiol. When applied to the skin, estradiol is absorbed through the skin into the bloodstream. | |
What is estradiol transdermal system (twice-weekly) used for? Estradiol transdermal system (twice-weekly) is used after menopause to:
| |
Who should not use estradiol transdermal system (twice-weekly)? Do not start using estradiol transdermal system (twice-weekly) if you:
Before you use estradiol transdermal system (twice-weekly), tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how estradiol transdermal system (twice-weekly) works. Estradiol transdermal system (twice-weekly) may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get new medicine. | |
How should I use estradiol transdermal system (twice-weekly)? For detailed instructions, see the step-by-step instructions for using estradiol transdermal system (twice-weekly) at the end of this Patient Information.
| |
How to Change estradiol transdermal system (twice-weekly)
| |
What are the possible side effects of estradiol transdermal system (twice-weekly)?
Side effects are grouped by how serious they are and how often they happen when you are treated.
Serious, but less common side effects include: | |
|
|
Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you:
Common side effects of estradiol transdermal system (twice-weekly) include: | |
|
|
These are not all the possible side effects of estradiol transdermal system (twice-weekly). For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or do not go away.
You may report side effects to FDA at 1-800-FDA-1088. You may report side effects to Mylan at 1-877-446-3679 (1-877-4-INFO-RX). | |
What can I do to lower my chances of getting a serious side effect with estradiol transdermal system (twice-weekly)?
| |
How should I store and throw away used estradiol transdermal system (twice-weekly) patches?
Keep estradiol transdermal system (twice-weekly) and all medicines out of the reach of children.
General information about safe and effective use of estradiol transdermal system (twice-weekly) Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use estradiol transdermal system (twice-weekly) for conditions for which it was not prescribed. Do not give estradiol transdermal system (twice-weekly) to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about estradiol transdermal system (twice-weekly) that is written for health professionals. For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). | |
What are the ingredients in estradiol transdermal system (twice-weekly)? Active ingredient: estradiol Inactive ingredients: a translucent polyolefin backing film, brown ink, silicone and acrylic adhesives, dipropylene glycol, povidone, oleyl alcohol, and a polyester release liner. Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A. | |
This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.
Estradiol Transdermal System, USP (Twice-Weekly)
(es″ tra dye′ ol)
Read this Instructions for Use before you start using estradiol transdermal system (twice-weekly) and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment.
1. Determine Your Schedule for Your Twice-a-Week Application
| |
 |
|
2. Where to Apply Estradiol Transdermal System (Twice-Weekly)
| |
 |
|
3. Before You Apply Estradiol Transdermal System (Twice-Weekly)
| |
 | Make sure your skin is:
|
4. How to Apply Estradiol Transdermal System (Twice-Weekly)
| |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Note:
5. Throwing Away Your Used Patch
This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Revised: 6/2025
ETSTW:R13
Includes 8 Systems
NDC 0378-4644-26 Rx only
Estradiol
Transdermal System, USP
(Twice-Weekly)
0.025mg/day
Important: Package not child-resistant.
Keep out of the reach of children.
FOR TRANSDERMAL USE ONLY
Patient Instruction:
1. Start at notched corner, tear pouch open.
Remove patch from pouch.
2. Hold patch with protective liner facing you.
3. Peel off one side of protective liner and discard.
4. Apply sticky side of patch to clean and dry area
of the abdomen.
5. Carefully remove the other piece of protective
liner and discard. Press patch firmly in place.
Delivers 0.025 mg/day
Each 2.5 cm2 system contains estradiol, USP hemihydrate
equivalent to 0.41 mg of estradiol.
Inactive components: silicone adhesive, acrylic adhesive,
dipropylene glycol, povidone, oleyl alcohol, polyolefin
backing film, polyester release liner.
Apply immediately upon removal from pouch. Do not store
unpouched.
Store at 20° to 25°C (68° to 77°F). [See USP
Controlled Room Temperature.]
Usual Dosage: See prescribing information.
M4644:26:8C:R8
Mylan.com
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Includes 8 Systems
NDC 0378-4643-26 Rx only
Estradiol
Transdermal System, USP
(Twice-Weekly)
0.0375 mg/day
Important: Package not child-resistant.
Keep out of the reach of children.
FOR TRANSDERMAL USE ONLY
Patient Instruction:
1. Start at notched corner, tear pouch open.
Remove patch from pouch.
2. Hold patch with protective liner facing you.
3. Peel off one side of protective liner and discard.
4. Apply sticky side of patch to clean and dry area
of the abdomen.
5. Carefully remove the other piece of protective
liner and discard. Press patch firmly in place.
Delivers 0.0375 mg/day
Each 3.75 cm2 system contains estradiol, USP hemihydrate
equivalent to 0.62 mg of estradiol.
Inactive components: silicone adhesive, acrylic adhesive,
dipropylene glycol, povidone, oleyl alcohol, polyolefin
backing film, polyester release liner.
Apply immediately upon removal from pouch. Do not store
unpouched.
Store at 20° to 25°C (68° to 77°F). [See USP
Controlled Room Temperature.]
Usual Dosage: See prescribing information.
M4643:26:8C:R8
Mylan.com
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Includes 8 Systems
NDC 0378-4642-26 Rx only
Estradiol
Transdermal System, USP
(Twice-Weekly)
0.05 mg/day
Important: Package not child-resistant.
Keep out of the reach of children.
FOR TRANSDERMAL USE ONLY
Patient Instruction:
1. Start at notched corner, tear pouch open.
Remove patch from pouch.
2. Hold patch with protective liner facing you.
3. Peel off one side of protective liner and discard.
4. Apply sticky side of patch to clean and dry area
of the abdomen.
5. Carefully remove the other piece of protective
liner and discard. Press patch firmly in place.
Delivers 0.05 mg/day
Each 5.0 cm2 system contains estradiol, USP hemihydrate
equivalent to 0.82 mg of estradiol.
Inactive components: silicone adhesive, acrylic adhesive,
dipropylene glycol, povidone, oleyl alcohol, polyolefin
backing film, polyester release liner.
Apply immediately upon removal from pouch. Do not store
unpouched.
Store at 20° to 25°C (68° to 77°F). [See USP
Controlled Room Temperature.]
Usual Dosage: See prescribing information.
M4642:26:8C:R8
Mylan.com
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Includes 8 Systems
NDC 0378-4641-26 Rx only
Estradiol
Transdermal System, USP
(Twice-Weekly)
0.075 mg/day
Important: Package not child-resistant.
Keep out of the reach of children.
FOR TRANSDERMAL USE ONLY
Patient Instruction:
1. Start at notched corner, tear pouch open.
Remove patch from pouch.
2. Hold patch with protective liner facing you.
3. Peel off one side of protective liner and discard.
4. Apply sticky side of patch to clean and dry area
of the abdomen.
5. Carefully remove the other piece of protective
liner and discard. Press patch firmly in place.
Delivers 0.075 mg/day
Each 7.5 cm2 system contains estradiol, USP hemihydrate
equivalent to 1.23 mg of estradiol.
Inactive components: silicone adhesive, acrylic adhesive,
dipropylene glycol, povidone, oleyl alcohol, polyolefin
backing film, polyester release liner.
Apply immediately upon removal from pouch. Do not store
unpouched.
Store at 20° to 25°C (68° to 77°F). [See USP
Controlled Room Temperature.]
Usual Dosage: See prescribing information.
M4641:26:8C:R8
Mylan.com
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Includes 8 Systems
NDC 0378-4640-26 Rx only
Estradiol
Transdermal System, USP
(Twice-Weekly)
0.1 mg/day
Important: Package not child-resistant.
Keep out of the reach of children.
FOR TRANSDERMAL USE ONLY
Patient Instruction:
1. Start at notched corner, tear pouch open.
Remove patch from pouch.
2. Hold patch with protective liner facing you.
3. Peel off one side of protective liner and discard.
4. Apply sticky side of patch to clean and dry area
of the abdomen.
5. Carefully remove the other piece of protective
liner and discard. Press patch firmly in place.
Delivers 0.1 mg/day
Each 10.0 cm2 system contains estradiol, USP hemihydrate
equivalent to 1.64 mg of estradiol.
Inactive components: silicone adhesive, acrylic adhesive,
dipropylene glycol, povidone, oleyl alcohol, polyolefin
backing film, polyester release liner.
Apply immediately upon removal from pouch. Do not store
unpouched.
Store at 20° to 25°C (68° to 77°F). [See USP
Controlled Room Temperature.]
Usual Dosage: See prescribing information.
M4640:26:8C:R8
Mylan.com
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 248478 | estradiol 0.025 MG/Day Twice Weekly Transdermal System | PSN | 14 |
| 241946 | estradiol 0.0375 MG/Day Twice Weekly Transdermal System | PSN | 14 |
| 242891 | estradiol 0.05 MG/Day Twice Weekly Transdermal System | PSN | 14 |
| 1149632 | estradiol 0.075 MG/Day Twice Weekly Transdermal System | PSN | 14 |
| 242892 | estradiol 0.1 MG/Day Twice Weekly Transdermal System | PSN | 14 |
| 248478 | 84 HR estradiol 0.00104 MG/HR Transdermal System | SCD | 14 |
| 241946 | 84 HR estradiol 0.00156 MG/HR Transdermal System | SCD | 14 |
| 242891 | 84 HR estradiol 0.00208 MG/HR Transdermal System | SCD | 14 |
| 1149632 | 84 HR estradiol 0.00313 MG/HR Transdermal System | SCD | 14 |
| 242892 | 84 HR estradiol 0.00417 MG/HR Transdermal System | SCD | 14 |
| 248478 | estradiol 0.00104 MG/HR 84 HR Transdermal Patch | SY | 14 |
| 241946 | estradiol 0.00156 MG/HR 84 HR Transdermal Patch | SY | 14 |
| 242891 | estradiol 0.00208 MG/HR 84 HR Transdermal Patch | SY | 14 |
| 1149632 | estradiol 0.00313 MG/HR 84 HR Transdermal Patch | SY | 14 |
| 242892 | estradiol 0.00417 MG/HR 84 HR Transdermal Patch | SY | 14 |
| 248478 | estradiol 0.025 MG/Day Twice Weekly Transdermal Patch | SY | 14 |
| 248478 | estradiol 0.025 MG/Day Twice Weekly Transdermal System | SY | 14 |
| 241946 | estradiol 0.0375 MG/Day Twice Weekly Transdermal System | SY | 14 |
| 242891 | estradiol 0.05 MG/Day Twice Weekly Transdermal System | SY | 14 |
| 1149632 | estradiol 0.075 MG/Day Twice Weekly Transdermal System | SY | 14 |
| 242892 | estradiol 0.1 MG/24HR Twice Weekly Transdermal Patch | SY | 14 |
| 242892 | estradiol 0.1 MG/Day Twice Weekly Transdermal System | SY | 14 |
| 241946 | estradiol 37.5 MCG/Day Twice Weekly Transdermal Patch | SY | 14 |
| 242891 | estradiol 50 MCG/Day Twice Weekly Transdermal Patch | SY | 14 |
| 1149632 | estradiol 75 MCG/Day Twice Weekly Transdermal Patch | SY | 14 |
| Class | Version | Type | Effective |
|---|---|---|---|
| ESTRADIOL Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0378-4640-16 | Estradiol | 3.5 d in 1 PATCH | PATCH | 3.5 | 14 | |
| 0378-4640-16 | Estradiol | 1 in 1 POUCH | PATCH | 1 | 14 | |
| 0378-4640-26 | Estradiol | 8 in 1 CARTON | PATCH | 8 | 14 | |
| 0378-4641-16 | Estradiol | 3.5 d in 1 PATCH | PATCH | 3.5 | 14 | |
| 0378-4641-16 | Estradiol | 1 in 1 POUCH | PATCH | 1 | 14 | |
| 0378-4641-26 | Estradiol | 8 in 1 CARTON | PATCH | 8 | 14 | |
| 0378-4642-16 | Estradiol | 1 in 1 POUCH | PATCH | 1 | 14 | |
| 0378-4642-16 | Estradiol | 3.5 d in 1 PATCH | PATCH | 3.5 | 14 | |
| 0378-4642-26 | Estradiol | 8 in 1 CARTON | PATCH | 8 | 14 | |
| 0378-4643-16 | Estradiol | 3.5 d in 1 PATCH | PATCH | 3.5 | 14 | |
| 0378-4643-16 | Estradiol | 1 in 1 POUCH | PATCH | 1 | 14 | |
| 0378-4643-26 | Estradiol | 8 in 1 CARTON | PATCH | 8 | 14 | |
| 0378-4644-16 | Estradiol | 3.5 d in 1 PATCH | PATCH | 3.5 | 14 | |
| 0378-4644-16 | Estradiol | 1 in 1 POUCH | PATCH | 1 | 14 | |
| 0378-4644-26 | Estradiol | 8 in 1 CARTON | PATCH | 8 | 14 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0378-4644-16 | EA - Each | 0378-4644 | c7767638-10b3-4ddf-a8fd-9d161292f233 | 1 | 2018-05-09 |
| 0378-4644-26 | EA - Each | 0378-4644 | 670f7ffa-eeac-419d-9f45-54e37247e376 | 1 | 2015-01-05 |
| 0378-4643-16 | EA - Each | 0378-4643 | 2abb63c1-0d40-4dd3-bc7f-373a63e1802e | 1 | 2018-05-09 |
| 0378-4643-26 | EA - Each | 0378-4643 | e4fe80c3-f5cd-4dfe-af1a-a7ee72e81584 | 1 | 2015-01-05 |
| 0378-4642-16 | EA - Each | 0378-4642 | 27fd7549-18e4-4e65-9d8b-dbe7366c03fd | 1 | 2018-05-09 |
| 0378-4642-26 | EA - Each | 0378-4642 | 98597f90-177c-49ef-9243-e11eebad7983 | 1 | 2015-01-05 |
| 0378-4641-16 | EA - Each | 0378-4641 | c16c873b-37ad-4ce8-b16a-869e2ff3b8a3 | 1 | 2018-05-09 |
| 0378-4641-26 | EA - Each | 0378-4641 | aa9e71af-dae5-41f5-904f-6cbe7bd5db60 | 1 | 2015-01-05 |
| 0378-4640-16 | EA - Each | 0378-4640 | 81e067bd-0cfe-4d33-a5cc-0486591d79ba | 1 | 2018-05-09 |
| 0378-4640-26 | EA - Each | 0378-4640 | e2f686e5-ad78-4e02-8c99-6791252ed2b6 | 1 | 2015-01-05 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ESTRADIOL | ACTIVE INGREDIENT | 4TI98Z838E | 4 | |
| ESTRADIOL | ACTIVE MOIETY | 4TI98Z838E | 4 | |
| DIPROPYLENE GLYCOL | INACTIVE INGREDIENT | E107L85C40 | 4 | |
| OLEYL ALCOHOL | INACTIVE INGREDIENT | 172F2WN8DV | 4 | |
| POVIDONES | INACTIVE INGREDIENT | FZ989GH94E | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0378-4644 | 0378-4644-16, 0378-4644-26 |
| 0378-4643 | 0378-4643-16, 0378-4643-26 |
| 0378-4642 | 0378-4642-16, 0378-4642-26 |
| 0378-4641 | 0378-4641-16, 0378-4641-26 |
| 0378-4640 | 0378-4640-16, 0378-4640-26 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| POVIDONES | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| POVIDONES | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| POVIDONES | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | SYSTEM / TRANSDERMAL | 6 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | SYSTEM / TRANSDERMAL | 6.12 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | FILM, EXTENDED RELEASE / TRANSDERMAL | 7.45 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| DIPROPYLENE GLYCOL | DIPROPYLENE GLYCOL | E107L85C40 | FILM, EXTENDED RELEASE / TRANSDERMAL | 296 mg | ||
| OLEYL ALCOHOL | OLEYL ALCOHOL | 172F2WN8DV | GEL / TRANSDERMAL | 1.5 %w/w |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A201675-001 | ESTRADIOL | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | |
| A201675-002 | ESTRADIOL | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | |
| A201675-003 | ESTRADIOL | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | |
| A201675-004 | ESTRADIOL | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | |
| A201675-005 | ESTRADIOL | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 |
| Application-product | TE code |
|---|---|
| A201675-001 | AB1 |
| A201675-002 | AB1 |
| A201675-003 | AB1 |
| A201675-004 | AB1 |
| A201675-005 | AB1 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A201675-001 | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A201675-002 | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A201675-003 | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A201675-004 | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A201675-005 | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A201675-001 | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A201675-002 | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A201675-003 | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A201675-004 | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A201675-005 | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A201675-001 | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A201675-002 | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A201675-003 | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A201675-004 | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A201675-005 | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-001 | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-002 | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-003 | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-004 | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-005 | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-001 | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-002 | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-003 | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-004 | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-005 | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-001 | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-002 | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-003 | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-004 | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-005 | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-001 | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-002 | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-003 | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-004 | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-005 | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-001 | ESTRADIOL | 0.025MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-002 | ESTRADIOL | 0.0375MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-003 | ESTRADIOL | 0.05MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-004 | ESTRADIOL | 0.075MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-005 | ESTRADIOL | 0.1MG/24HR | SYSTEM / TRANSDERMAL | AB1 | 2014-12-19 | b8a1b40f171c… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A201675-001 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A201675-002 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A201675-003 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A201675-004 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A201675-005 | AB1 | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A201675-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A201675-002 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A201675-003 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A201675-004 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A201675-005 | AB1 | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A201675-001 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A201675-002 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A201675-003 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A201675-004 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A201675-005 | AB1 | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-001 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-002 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-003 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-004 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A201675-005 | AB1 | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-001 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-002 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-003 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-004 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201675-005 | AB1 | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-001 | AB1 | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-002 | AB1 | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-003 | AB1 | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-004 | AB1 | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A201675-005 | AB1 | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-001 | AB1 | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-002 | AB1 | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-003 | AB1 | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-004 | AB1 | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201675-005 | AB1 | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-001 | AB1 | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-002 | AB1 | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-003 | AB1 | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-004 | AB1 | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201675-005 | AB1 | 1 | b8a1b40f171c… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Estradiol | ESTRADIOL | Mylan Pharmaceuticals Inc. | d28bec8f-762e-4f05-a20d-96a42970d6a7 | 2025-06-17 | Boxed warning, Warnings, Adverse reactions | 0378-4641-16 0378-4644-16 0378-4641-26 0378-4642-16 0378-4642-26 0378-4643-26 0378-4640-26 0378-4640-16 0378-4644-26 0378-4643-16 0378-4644 0378-4641 0378-4640 0378-4643 0378-4642 00378464126 00378464316 00378464116 00378464226 00378464216 00378464416 00378464326 00378464026 00378464426 00378464016 e1deb37a-8362-4275-a04c-7abcbb2e9f56 d28bec8f-762e-4f05-a20d-96a42970d6a7 |
Adverse event summaries are temporarily unavailable. Other product information remains available.